For six years, COVID-19 vaccine manufacturers operated under a legal shield that made them functionally untouchable. If their product injured you, tough luck. The emergency declarations issued in early 2020 provided broad immunity to manufacturers and the people who administered the shots.
The man who spent those years being called a conspiracy theorist for questioning the arrangement just ended it.
Health Secretary Robert F. Kennedy Jr. announced on June 30 that he is terminating the emergency use authorization declarations that have protected vaccine makers like Pfizer and Moderna from lawsuits since the pandemic began. "Americans deserve a regulatory system that is transparent, accountable, and rooted in the rule of law," Kennedy said in his announcement, as reported by ZeroHedge.
The declarations — which covered vaccines, treatments, and medical devices including COVID-19 tests — were first issued in 2020 under the pandemic emergency. The COVID-19 public health emergency itself expired in May 2023. The declarations did not.
In fact, they were extended. Former Health Secretary Xavier Becerra renewed them in 2024, pushing the expiration through the end of 2029 — six years past the point when the government's own public health emergency had lapsed. Becerra justified the extension by claiming COVID-19 "continues to present a credible risk of a future public health emergency."
Kennedy's termination notice rejected that logic directly. "Circumstances no longer exist to justify emergency use of drugs and biological products during the COVID-19 pandemic," he wrote. The vaccine and drug declarations will terminate on June 29, 2027, giving manufacturers 12 months to transition. Medical device declarations expire sooner — December 26, 2026, a 180-day window.
The FDA had already revoked emergency authorization for COVID-19 vaccines in 2025, transitioning them to the standard approval pathway across all age groups. Kennedy's move strips the remaining legal infrastructure that emergency status provided — most critically, the liability protections.
"By ending these COVID-19 emergency use authorization declarations, we're reinforcing public confidence that emergency authorities are temporary and targeted," Kennedy said. The Department of Health and Human Services indicated officials plan to notify Congress of the development.
The timeline tells its own story. The emergency ended in 2023. The FDA pulled emergency authorization in 2025. And yet the liability shield — the part that actually mattered to pharmaceutical companies' bottom lines — was scheduled to run through 2029. The emergency was over everywhere except the one place that protected corporate balance sheets.
Pharmaceutical companies built compliance and legal strategies around the assumption that emergency declarations were effectively permanent. Becerra's 2024 extension reinforced that assumption. The 12-month wind-down Kennedy provided is generous by regulatory standards, but it represents something the industry hadn't priced in: accountability.
Emergency powers were designed for emergencies. The emergency ended three years ago. The protections those powers granted just caught up.
